PURE Bioscience to Present at Rodman & Renshaw Annual Global Investment Conference

SAN DIEGO, CA--(Marketwired - Aug 21, 2014) - PURE Bioscience, Inc. ( OTCQB : PURE ), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that Hank R. Lambert, CEO, will present at the Rodman & Renshaw Annual Global Investment Conference sponsored by H.C. Wainwright & Co., LLC., on Wednesday, September 10th, at 1:40pm EDT, at the New York Palace Hotel.

Lambert will discuss management's progress in commercializing PURE's patented SDC antimicrobial technology as a novel and proprietary food safety solution, including:

  • PURE's regulatory submission status for the use of SDC as direct food contact processing aid.
  • PURE's commercialization status of PURE Hard Surface Disinfectant into national-brand foodservice and food manufacturing markets.

If you are an institutional investor, and would like to attend the Company's presentation, please click on the following link (www.rodm.com) to register for the Rodman & Renshaw conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

The presentation will be webcast live and slides may be accessed on the Company's website, http://www.purebio.com/about/investor_relations. The presentation will be archived for 90 days.

About PURE Bioscience, Inc.
PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena -- providing solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.

Forward-looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company's cash position and liquidity requirements, the Company's failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission, including our annual report on Form 10-K filed October 24, 2013. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.